Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2010-09-02 Regulatory Filings
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Clinical Trial Recruitment Completed Ahead of Schedule 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 3 September 2010 from CBio Limited, reporting the full recruitment of 150 patients into a clinical trial for their drug XToll. It discusses progress on clinical trials, patent issues, and manufacturing discussions. There are no financial statements, regulatory certifications, or detailed financial data. The content is an update on clinical trial progress and company milestones rather than a financial report or regulatory filing. The document is relatively short (4704 characters) and reads as a corporate announcement to the market about operational progress. This fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and company updates that do not fit other specific categories.
2010-09-02 English
Appendix 3B 9 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class and number of securities issued, terms, escrow periods, and application for quotation on the ASX (Australian Securities Exchange). It includes sections on the purpose of the issue, quotation agreement, and detailed schedules of securities issued and not quoted. The document is a formal announcement related to new share issues and capital changes, specifically an Appendix 3B form used in Australian market disclosures for new securities issuance and quotation application. It does not contain financial statements, earnings data, or management discussion, nor is it a report or presentation. Therefore, it fits the category of a Share Issue/Capital Change announcement.
2010-08-30 English
Preliminary Final Report 16 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'Appendix 4E Preliminary Final Report 30 June 2010' and contains detailed financial statements including Statement of Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity, Statement of Cash Flows, and Notes to Financial Information for the year ended 30 June 2010. It includes comprehensive financial data and analysis for a full fiscal year, indicating it is a full annual financial report. The document also mentions the financial report is in the process of being audited, which is typical for preliminary annual reports. The length of the document (15,000 characters) and the presence of detailed financial statements confirm it is not merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K equivalent). FY 2010
2010-08-29 English
Release from Escrow 1 page ?Kb
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement addressed to the ASX Limited Company Announcements Office regarding the release of securities from escrow. It details specific dates and quantities of shares and convertible notes being released from escrow restrictions. There is no financial data, report, or analysis included, and the document is relatively short (1697 characters). It is an announcement about share capital changes related to escrow release, which fits best under the category of Share Issue/Capital Change (SHA).
2010-08-26 English
Cornerstone IP Secured and Clinical Trial Update 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 23 August 2010 from CBio Limited, reporting on the strengthening of its patent position and updates on recruitment into a clinical trial. It discusses patent grants and extensions, clinical trial recruitment progress, and ongoing capital raising activities. There are no financial statements, quarterly or annual results, or detailed financial data presented. The content is primarily an operational update and patent status announcement rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital/Financing Update specifically. The document is a general regulatory announcement about company developments and patent status, which aligns best with the Regulatory Filings (RNS) category as a general announcement that does not fit other specific categories.
2010-08-22 English
Appendix 3B 10 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of convertible notes, terms of the securities, number and class of securities, and application for quotation on the ASX. It includes sections on the securities issued, their terms, ranking, issue price, purpose, and quotation agreement. The document is a formal announcement related to a new issue of securities and application for quotation, consistent with regulatory requirements for capital raising disclosures. It does not contain financial statements, management discussion, or audit information, nor is it a report or transcript. The content aligns with announcements about capital structure changes and fundraising activities. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length (over 14,000 characters) and detailed content support a high confidence in this classification.
2010-08-18 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.